Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Award amountNot stated
Records whose eligibility text names Hispanic-serving Institutions. Naming is not eligibility: a programme may name a designation to set aside part of a pool, to state a preference, or to exclude. Read each record's own eligibility field before relying on it.
139 of 139 records carry a stated deadline; 0 are rolling and the rest read Not stated.
Counted from linked records only.